Zydus Lifesciences has announced that the U.S. Food and Drug Administration (USFDA) has granted final approval for Indocyanine Green for Injection, USP, 25 mg/vial, with eligibility for 180-day Competitive Generic Therapy (CGT) exclusivity. The approval represents an important milestone for the company, reflecting its continued focus on expanding its portfolio of complex injectable generic medicines while addressing areas with limited generic competition. Under the CGT pathway, the first approved applicant receives a period of market exclusivity following commercial launch, encouraging the development of generic medicines for products with inadequate competition.
Indocyanine Green is a sterile diagnostic dye widely used in clinical practice for hepatic function assessment, cardiac output determination, and ophthalmic angiography. In recent years, it has also become an indispensable imaging agent in fluorescence-guided surgical procedures, enabling surgeons to improve visualization of blood vessels, lymphatic structures, tissue perfusion, and anatomical boundaries during minimally invasive and oncologic surgeries. Its growing clinical utility has increased demand for reliable and affordable generic formulations across healthcare settings.
The USFDA approval reinforces Zydus’ capabilities in developing technically challenging injectable products that meet stringent regulatory and manufacturing standards. By obtaining first-to-market status under the CGT program, the company is positioned to strengthen its presence in the U.S. generic pharmaceutical market while supporting broader patient access to high-quality, cost-effective diagnostic products. The approval also aligns with Zydus’ long-term strategy of investing in differentiated generics and complex formulations that offer meaningful commercial opportunities and clinical value.
The CGT designation was established by the FDA to stimulate generic drug development in markets with inadequate competition. Eligible first-approved applicants may receive 180 days of exclusivity, during which approval of competing ANDAs for the same product is generally deferred following commercial launch. This incentive promotes earlier availability of affordable generic medicines while fostering continued innovation in generic drug development. Overall, the approval of Indocyanine Green for Injection further expands Zydus’ U.S. product portfolio and underscores its commitment to delivering high-quality, accessible healthcare solutions for patients and healthcare providers worldwide.
